Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 16742
Country/Region: Ethiopia
Year: 2017
Main Partner: Ministry of National Defense - Ethiopia
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $2,366,916 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $160,091
Care: TB/HIV (HVTB) $75,614
Care: Pediatric Care and Support (PDCS) $9,921
Laboratory Infrastructure (HLAB) $30,000
Strategic Information (HVSI) $45,054
Testing: HIV Testing and Counseling (HVCT) $70,731
Sexual Prevention: Other Sexual Prevention (HVOP) $1,207,852
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $7,579
Treatment: Adult Treatment (HTXS) $736,370
Treatment: Pediatric Treatment (PDTX) $23,704
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2018 54
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2018 40
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2018 60
GEND_GBV Number of people receiving post-GBV care 2018 100
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 54,159
PMTCT_ART Already on ART at beginning of current pregnancy 2018 37
PMTCT_ART New on ART 2018 20
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2018 57
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 3,041
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2018 60
PMTCT_EID Number of infants with a negative virological test result between 2 and 12 months of birth 2018 11
PMTCT_EID Number of infants with a negative virological test result within 2 months of birth 2018 47
PMTCT_EID Number of infants with a positive virological test result between 2 and 12 months of birth 2018 1
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2018 1
PMTCT_STAT By Age (Numerator): 15-19 2018 152
PMTCT_STAT By Age (Numerator): 20-24 2018 1,064
PMTCT_STAT By Age (Numerator): 25-49 2018 1,825
PMTCT_STAT By Number of known positives: 15-19 2018 2
PMTCT_STAT By Number of known positives: 20-24 2018 14
PMTCT_STAT By Number of known positives: 25-49 2018 23
PMTCT_STAT By Number of new negative: 15-19 2018 149
PMTCT_STAT By Number of new negative: 20-24 2018 1,043
PMTCT_STAT By Number of new negative: 25-49 2018 1,789
PMTCT_STAT By Number of new positives: 15-19 2018 1
PMTCT_STAT By Number of new positives: 20-24 2018 7
PMTCT_STAT By Number of new positives: 25-49 2018 13
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 3,041
PMTCT_STAT_den By Age (Denominator): <15-19 2018 152
PMTCT_STAT_den By Age (Denominator): 20-24 2018 1,067
PMTCT_STAT_den By Age (Denominator): 25-49 2018 1,829
PP_PREV Age/sex: 15-19 Female 2018 1,714
PP_PREV Age/sex: 15-19 Male 2018 8,445
PP_PREV Age/sex: 20-24 Female 2018 1,822
PP_PREV Age/sex: 20-24 Male 2018 8,974
PP_PREV Age/sex: 25-49 Female 2018 3,950
PP_PREV Age/sex: 25-49 Male 2018 35,497
PP_PREV Age/sex: 50+ Female 2018 55
PP_PREV Age/sex: 50+ Male 2018 264
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2018 60,721
PP_PREV Sum of Age/Sex disaggregates 2018 60,721
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 5
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 24
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 29
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 29
TB_ART_den Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 5
TB_ART_den Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 24
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 65
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 294
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2018 359
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2018 366
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 66
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 66
TX_CURR Aggregated Age/Sex: <15 Female 2018 86
TX_CURR Aggregated Age/Sex: <15 Male 2018 80
TX_CURR Aggregated Age/Sex: 15+ Female 2018 1,533
TX_CURR Aggregated Age/Sex: 15+ Male 2018 4,599
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 6,298
TX_CURR Sum of Aggregated Age/Sex <15 2018 166
TX_CURR Sum of Aggregated Age/Sex 15+ 2018 6,132
TX_CURR Sum of Aggregated Age/Sex disaggregates 2018 6,298
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2018 8
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2018 8
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2018 150
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2018 449
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 615
TX_NEW Pregnancy status 2018 20
TX_NEW Sum of Aggregated Age/Sex disaggregates 2018 615
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 6,265
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 5,307
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 32
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 15
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 33
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 15
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 1,104
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 199
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 3,311
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 598
TX_PVLS Numerator: Indication: Routine 2018 4,480
TX_PVLS Numerator: Indication: Targeted 2018 827
TX_PVLS Numerator: Preg/BF by Indication: Pregnant Routine 2018 22
TX_PVLS Numerator: Preg/BF by Indication: Pregnant Targeted 2018 5
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 46
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 19
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 47
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 21
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 1,226
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 307
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 3,679
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 920
TX_PVLS_den Denominator: Indication: Routine 2018 4,998
TX_PVLS_den Denominator: Indication: Targeted 2018 1,267
TX_PVLS_den Denominator: Preg/BF by Indication: Pregnant Routine 2018 24
TX_PVLS_den Denominator: Preg/BF by Indication: Pregnant Targeted 2018 6
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 7
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 8
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 128
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 385
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 528
TX_RET Numerator by Status: Pregnant 2018 33
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 587
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 8
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 8
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 143
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 428
TX_RET_den Denominator by Status: Pregnant 2018 37
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 15,285
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 245
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2018 2
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 5
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 79
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 159
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 2
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 5
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2018 79
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2018 159
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2018 206
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2018 17
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2018 52
TX_TB_den Denominator: By Screen Result: Negative 2018 14,979
TX_TB_den Denominator: By Screen Result: Positive 2018 306
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2018 275
Cross Cutting Budget Categories and Known Amounts Total: $36,000
Gender: Gender Based Violence (GBV) $36,000
GBV Prevention
Implementation
Capacity building